Diabetes Overview 

Globally, 589 million people suffer from diabetes, causing 3.4 million deaths annually. The diabetes drug market was approaching 80 billion USD in 2025 and is projected to exceed 153.4 billion USD by 2033.

This figure illustrates the evolving market share of existing diabetes medications, showing that small-molecule drugs are growing year over year. Since PS-001 is a small-molecule novel drug, it aligns perfectly with the current trend in diabetes treatment.

• Early-to-Mid-Stage Patients primarily use small-molecule drugs, accounting for 55% of the current diabetes market.

• DPP4 inhibitors and GLP-1 analogs represent a relatively newer category, with their market share continuously growing, currently reaching 30% of the total diabetes drug market.

• Late-Stage Patients primarily use insulin and insulin analogues, which account for 45% of the diabetes drug market.

Our target market is the growing 30% segment currently addressed by DPP4 inhibitors and GLP-1 analogs.

Diabetes in Numbers

• 589 million (11.1%) adults aged 20–79 have diabetes; this is projected to rise to 853 million (13%) by 2050. 
• 252 million people are living with undiagnosed diabetes. 
• 158 million (25%) people with diabetes are aged over 65. 
• 635 million people (12%) have prediabetes (Impaired Glucose Tolerance). 
• $1 trillion (12%) of global health expenditure was spent on diabetes (2024). 
• 3.4 million people (9.3%) died due to diabetes in 2024. 
• 9.1 million people have Type 1 Diabetes, 69% of whom are aged 20–59. 
• 23 million live births (20%) were affected by hyperglycemia in pregnancy (gestational high blood sugar).